Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	25 mg XEN1101	114
Overall Study	STARTED	20 mg XEN1101	51
Overall Study	STARTED	10 mg XEN1101	46
Overall Study	STARTED	Placebo	114
Overall Study	COMPLETED	25 mg XEN1101	88
Overall Study	COMPLETED	20 mg XEN1101	43
Overall Study	COMPLETED	10 mg XEN1101	45
Overall Study	COMPLETED	Placebo	109
Overall Study	NOT COMPLETED	25 mg XEN1101	26
Overall Study	NOT COMPLETED	20 mg XEN1101	8
Overall Study	NOT COMPLETED	10 mg XEN1101	1
Overall Study	NOT COMPLETED	Placebo	5

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03796962/flow